Navigation Links
SemBioSys announces 2007 financial and operational results
Date:3/17/2008

oducts in the U.S. market containing

Hydresia(TM), two body washes and a hand soap.

- Produced sufficient safflower-produced ImmunoSphere(TM) Feed Additive

in Chile and the United States to enable the next stage of the

Company's development and commercialization plans.

Financials

Please note that prior to the third quarter of 2007, SemBioSys operated under one segment. During the third quarter, Botaneco completed the construction of its manufacturing facility and SemBioSys began operating in two reportable segments: (i) the Biopharmaceutical, Animal Health, and Nutritional Oils segment focused on the Company's lead pharmaceutical candidates, recombinant human insulin and Apo AI, in addition to its animal health product, ImmunoSphere(TM) and nutritional oils, DHA and GLA and (ii) the Specialty Ingredients segment which will manufacture and market branded lines of naturally derived base emulsions and delivery systems used in the development of cosmetic, personal care and prescription topical/dermatology products through the Botaneco subsidiaries.

Total revenue for the twelve-month period ended December 31, 2007 was $1,222,823 compared with $523,258 for the corresponding period in 2006. The difference is due mainly to a license fee payment earned from our collaboration agreement with Martek BioSciences Corporation in the first half of 2007, and from product sales from Hydresia(TM).

Total expenditures for the year ended December 31, 2007 were $17,599,775 compared with $15,082,560 for the year ended December 31, 2006.

Research and development expenses for the twelve-month period ended December 31, 2007 were $8,044,121, compared with $5,480,972 for the same period last year. The increase in research and development costs is primarily from increased laboratory supplies, personnel and outsourcing costs related to preclinical activity and the related support costs in all areas of research and development wit
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
2. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
3. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
4. SemBioSys signs option agreement for safflower-produced food ingredient
5. SemBioSys announces 2007 third quarter results
6. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
7. SemBioSys updates Apo AI development program
8. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
9. Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management
10. BioMed Realty Trust Announces Increase in Quarterly Common Stock Dividend
11. Emisphere Technologies, Inc. Announces Conference Call for 2007 Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... May 24, 2013 In a ... industry suppliers will present technologies with applications in ... annual SPIE Optics and Photonics symposium ... SPIE, the international society for optics and ... multidisciplinary optical sciences and technology meeting in North ...
(Date:5/24/2013)... Toronto, Canada (PRWEB) May 24, 2013 ... selective barriers, and uptake or efflux transporters at the ... may be related to unbound fractions in the tissue ... understanding of these disposition challenges is required to guide ... and to identify any species-dependent variables that may impact ...
(Date:5/23/2013)... stopped breathing, his collapsed bronchus blocking the crucial flow ... watched helplessly, just praying that somehow the dire predictions ... had a good chance of not leaving the hospital ... Kaiba. "At that point, we were desperate. Anything that ... it." , They found hope at the University of ...
(Date:5/23/2013)... 2013 Patheon Inc ., a ... the global pharmaceutical industry, will host a complimentary webinar ... Testing” on Tuesday, June 4, 2013 at 11 a.m. ... required to comply with regulations for cleaning validation. ... scientific underpinning and little evaluation of risk. Some ...
Breaking Biology Technology:See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 2See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 3See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 4DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2
... up to ... $385 million plus royalties -, PALO ALTO, ... announced today that it has entered into an agreement,granting exclusive ... countries to the Menarini Group. Menarini,with its significant pan-European presence, ...
... Management,Slate of InSite Vision, Including the Chairman and ... Sept. 11 PTV Sciences,("PTV"), a healthcare venture ... that RiskMetrics Group -(Formerly known as ISS), the ... that the,stockholders of InSite Vision Incorporated (Amex: ...
... 11 A project to advance,research and improve ... by a,new $1.6 million, three-year cooperative agreement with ... The agreement, intended to bring better care to ... National Fragile X Foundation (NFXF),the CDC,s National Center ...
Cached Biology Technology:CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group 2CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group 3CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group 4CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group 5RiskMetrics (ISS), An Independent Proxy Advisory Firm, Recommends Voting the GOLD Card for Four of PTV's Nominees: Anderson, McInerney, Melrose, and O'Holla 2RiskMetrics (ISS), An Independent Proxy Advisory Firm, Recommends Voting the GOLD Card for Four of PTV's Nominees: Anderson, McInerney, Melrose, and O'Holla 3RiskMetrics (ISS), An Independent Proxy Advisory Firm, Recommends Voting the GOLD Card for Four of PTV's Nominees: Anderson, McInerney, Melrose, and O'Holla 4$1.6 Million Agreement to Accelerate Fragile X Research, Inspire Hope 2
(Date:5/24/2013)... combat metastatic cancer , Cancer cells spread and ... system. Stimulation of the immune system can help to ... cause the immune system to ignore cancer cells. Regulatory ... the immune system response. In this issue of the ... Ronald Levy at Stanford University found that regulatory T ...
(Date:5/24/2013)... against Alzheimer,s disease, scientists have focused among other factors ... After all, it is the accumulation of A-beta that causes ... point for the formation of A-beta is APP. Alessia Soldano ... the function of APPL the fruit-fly version of APP ... Alessia Soldano (VIB/KU Leuven): "We have discovered that APPL ensures ...
(Date:5/23/2013)... National Laboratory honored more than 165 staff for ... at PNNL,s annual Intellectual Property Commercialization Recognition & ... Energy national laboratory named materials scientist Jun Liu ... battery materials that can store large amounts of ... reduce the time it takes to charge cell ...
Breaking Biology News(10 mins):JCI early table of contents for May 24, 2013 2JCI early table of contents for May 24, 2013 3JCI early table of contents for May 24, 2013 4JCI early table of contents for May 24, 2013 5JCI early table of contents for May 24, 2013 6JCI early table of contents for May 24, 2013 7JCI early table of contents for May 24, 2013 8A new strategy required in the search for Alzheimer's drugs? 2PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2
... , DNA-Prokids ( http://www.dna-prokids.org ), an international project ... victims and their relatives, was officially presented today, at the ... Traffic in human beings is one of the most ... century. According to data from the United Nations Office on ...
... rapid growth of institutional Memberships for open access ... of the "Online Reporting System" for its open ... BioMed Central,s cutting edge publishing platform, the new ... and help reduce the administrative costs associated with ...
... Stedim Biotech (SSB) and Adolf Kühner AG ,- Prototype ... ,Monthey, 19. Mai 2009 / b3c newswire ... to the biopharmaceutical industry, expands its product offering with ... OrbShake bioreactors rely on orbital shaking principles for ...
Cached Biology News:DNA-Prokids: Genetic identification against traffic in human beings 2ExcellGene SA first company to offer contract manufacturing in 250 Liter OrbShake bioreactor 2ExcellGene SA first company to offer contract manufacturing in 250 Liter OrbShake bioreactor 3
... and M.W. Turner (1997). ... step-by-step methods for the ... molecules, the use of ... analytical probes and as ...
Request Info...
RABBIT ANTI PORCINE CARBOXYPEPTIDASE B...
... Maker, 1. Modular system for large ... up to six lab-cast or precast ... with 18- or 24-cm Immobiline DryStrip ... gel cassettes.Innovative design simplifies loading and ...
Biology Products: